Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes.

ABSTRACT:

Background

PD-L1 has been used as a biomarker to select patients for treatment of PD-1/PD-L1 inhibitors.

Materials and methods

In this study, we assessed the clinicopathological features of breast cancers that are associated with PD-L1 expression, as well as its relationship with other immune components and its prognostic significance.

Results

Totally 1752 cases were included in this cohort. PD-L1 expression in tumor-infiltrating immune cells (PD-L1-IC) expression and in tumor cells (PD-L1-TC) expression were identified in 34.2% and 10.1% of cases, respectively, and they showed a positive correlation with higher tumor grade, morphological apocrine features, presence of necrosis, and higher stromal tumor-infiltrating lymphocytes (sTIL). PD-L1-IC and PD-L1-TC expression

SUBMITTER: Ni Y 

PROVIDER: S-EPMC8982370 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature